Skip to Main Content

Paper Details

Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema.
Br J Ophthalmol
5
2023
Author NameAffiliation
Mark C GilliesThe University of Sydney Save Sight Institute
Mark C GilliesSydney and Sydney Eye Hospital
Vuong NguyenThe University of Sydney Save Sight Institute
Hemal MehtaThe University of Sydney Save Sight Institute
Hemal MehtaRoyal Free London NHS Foundation Trust
Ian L McAllisterUniversity of Western Australia, Lions Eye Institute
  • 1 - 6

Datasets

Release 1.2